A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy

Teva Neuroscience, Inc.257 enrolled

Overview

This study has patients responding to two sets of surveys that will tell their doctor or nurse about their readiness to begin self-injection. In addition, patients will have their self-injection observed and evaluated on up to three visits

Study Type

OBSERVATIONAL

Enrollment

257

Conditions

Multiple Sclerosis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or Female, 18 years of age or older, with diagnosis of RRMS 2. Naive to treatment or previously treated with an IFN. Exclusion Criteria: 1. Not eligible for treatment based on clinical criteria and current indication. 2. Unable to respond to surveys or provide informed consent.

Outcomes

Primary Outcomes

Adherence of self-injection assessed by self-report at each follow-up visit

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.